en
Nieuwsbrief
Cases

Confo Therapeutics

  • Start-ups & scale-ups
  • Life Sciences & Care
  • Portfolio Life Sciences & Care
  • Life sciences & care

We appreciate the strong and unwavering support of our investors that has brought our company to this stage. We look forward to further boosting our drug discovery platform and developing our portfolio of GPCR-modulating compounds.

Cedric Ververken, CEO at Confo Therapeutics

Confo Therapeutics is a spin-off of the Vrije Universiteit Brussel (VUB) and VIB. It was founded in 2015 by VIB and Capricorn Venture Partners with the support of MINTS, QBIC, V-Bio Ventures and PMV. The Ghent-based biotech company develops new drugs based on its ‘Confo technology’ and ‘ConfoBodies’ – antibodies derived from camelids.

The patented ConfoBodies can selectively stabilise G protein-coupled receptors (GPCRs) in specific conformations. This makes them valuable tools for drug discovery to treat severe diseases. Confo Therapeutics not only works on its own developments but also establishes promising partnerships with pharmaceutical companies. Lundbeck and Roche.

Partners in ambition at Confo Therapeutics

In fiscal year 2020, the workforce grew from 33 to 50 employees. End of November 2021, Confo Therapeutics concluded an important new partnership with the American biotechnology company Regeneron Pharmaceuticals. This demonstrates once again the potential of Confo’s technology platform for drug development.

PMV was engaged in Confo Therapeutics from the start and in 2019 also participated in the Series A financing round led by BioGeneration Ventures (BGV) and Wellington Partners. In this process, the growth company raised €30 million from new and existing financing partners.

In 2022, Confo Therapeutics is ready for a new round of financing, this time led by Brandon Capital Partners. Convinced by the biotech company’s strategy and the clear interest in the market, PMV also remains one of the investors in this capital round.

Contact our experts Life Sciences

Filip Goossens Principal investment manager filip.goossens@pmv.eu
Kenneth Wils Head of Life Sciences & Care kenneth.wils@pmv.eu +32 (0)2 274 63 83